Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources by Tura, Olga et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Absence of a relationship between immunophenotypic and colony 
enumeration analysis of endothelial progenitor cells in clinical 
haematopoietic cell sources
Olga Tura1, G Robin Barclay*1, Huw Roddie2, John Davies2 and 
Marc L Turner1
Address: 1SNBTS Adult Cell Therapy Group, Scottish Centre for Regenerative Medicine, University of Edinburgh School of Clinical Sciences, The 
Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK and 2NHS Lothian University Hospitals Division, Department of 
Haematology, Western General Hospital, Edinburgh, EH4 2XU, UK
Email: Olga Tura - Olga.Tura@ed.ac.uk; G Robin Barclay* - Robin.Barclay@ed.ac.uk; Huw Roddie - Huw.Roddie@luht.scot.nhs.uk; 
John Davies - John.Davies@luht.scot.nhs.uk; Marc L Turner - Marc.Turner@snbts.csa.scot.nhs.uk
* Corresponding author    
Abstract
Background:  The discovery of adult endothelial progenitor cells (EPC) offers potential for
vascular regenerative therapies. The expression of CD34 and VEGFR2 by EPC indicates a close
relationship with haematopoietic progenitor cells (HPC), and HPC-rich sources have been used to
treat cardiac and limb ischaemias with apparent clinical benefit. However, the laboratory
characterisation of the vasculogenic capability of potential or actual therapeutic cell autograft
sources is uncertain since the description of EPC remains elusive. Various definitions of EPC based
on phenotype and more recently on colony formation (CFU-EPC) have been proposed.
Methods: We determined EPC as defined by proposed phenotype definitions (flow cytometry)
and by CFU-EPC in HPC-rich sources: bone marrow (BM); cord blood (CB); and G-CSF-mobilised
peripheral blood (mPB), and in HPC-poor normal peripheral blood (nPB).
Results: As expected, the highest numbers of cells expressing the HPC markers CD34 or CD133
were found in mPB and least in nPB. The proportions of CD34+ cells co-expressing CD133 is of
the order mPB>CB>BM≈nPB. CD34+ cells co-expressing VEGFR2 were also most frequent in mPB.
In contrast, CFU-EPC were virtually absent in mPB and were most readily detected in nPB, the
source lowest in HPC.
Conclusion: HPC sources differ in their content of putative EPC. Normal peripheral blood, poor
in HPC and in HPC-related phenotypically defined EPC, is the richest source of CFU-EPC,
suggesting no direct relationship between the proposed EPC immunophenotypes and CFU-EPC
potential. It is not apparent whether either of these EPC measurements, or any, is an appropriate
indicator of the therapeutic vasculogenic potential of autologous HSC sources.
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Background
Until recently postnatal vascular repair and regeneration
was thought to result exclusively from angiogenesis, the
outgrowth of fully differentiated mature endothelial cells
(EC) from pre-existing blood vessels. The discovery that
mononuclear cells in peripheral blood have the potential
to differentiate into endothelial cells and may give rise to
de novo vasculogenesis [1-3], a process hitherto thought
only to occur in the developing embryo, has stimulated
growing interest in clinical use of locally injected autolo-
gous cells to promote revascularisation of ischaemic tis-
sue. These circulating adult endothelial progenitor cells
(EPC) appear to share a common precursor with haemat-
opoietic progenitor cells (HPC) which was first recognised
in early embryogenesis and termed the haemangioblast
[4-6].
HPC are routinely employed in clinical haematopoietic
reconstitution, commonly following myeloablative
chemotherapy for leukaemias when they are harvested for
autologous use during periods of remission. HPC for clin-
ical use were harvested initially from bone marrow, but
latterly are predominantly harvested by apheresis follow-
ing mobilisation of HPC from bone marrow to peripheral
blood (PBHPC) following administration of G-CSF. They
may also be harvested from allogeneic donors from the
same sources. Haematopoiesis is recognised to depend
upon the HPC dose administered for rapid and sustained
engraftment, and the haematopoietic potential of the
HPC graft is determined by the numbers of CD34-express-
ing mononuclear cells [7] or by expression of CD133
which may identify an earlier more pluripotent HPC pop-
ulation [8-10].
EPC have much in common with HPC and share the phe-
notypic markers CD34 and CD133. Thus they may be
regarded as a subset of the CD34+ or CD133+ mononu-
clear cells found in bone marrow and blood, and cells co-
expressing either of these markers together with VEGF-
receptor-2 (VEGFR2, also known as KDR) have been
ascribed endothelial progenitor activity [2,11-14]. How-
ever the ontogenic relationship between expression of
these markers and maturity, pluripotency and function is
not clear [9,10,15,16]. It is reported that VEGFR2 may be
co-expressed by subsets of cells expressing CD133 or
CD34 exclusively or jointly, and while VEGFR2 expression
has been associated with EPC activity it is not clear
whether all or any phenotypically definable subset of
these VEGFR2 expressing cells are exclusively vasculogenic
or whether they retain haematopoietic potential [11,17-
19]. Further, it appears that some circulating mononu-
clear cells with EPC potential may not clearly express
either CD133 or CD34 [20-22]. It now appears probable
that the EPC, like other tissue stem and progenitor cells,
are not a distinct entity with a unique definable pheno-
type but a continuum along a range of development [23-
26], the root of which is shared with haematopoietic stem
cells. Currently, many groups use their own often rela-
tively exclusive EPC definitions based on their experimen-
tal and/or clinical outcomes, but usually combining one,
two or three of the markers CD34; CD133; VEGFR2. This
makes it very difficult to interpret and compare results
between different studies.
In the face of an uncertain phenotype, EPC colony form-
ing unit (CFU) assays have emerged as alternative specific
enumeration system for EPC [21-23]. The CFU assay pro-
posed by Hill et al[27] determines early or spontaneous
CFU-EPC formation based on mononuclear cell colony
outgrowth over 5 days on fibronectin coated plates in sim-
ple medium without growth factors. Characteristic colo-
nies are evident even at low frequencies which would be
difficult to determine statistically by flow cytometry if the
phenotype of the colony forming cell were known. This
colony assay is now available as a standardized commer-
cial kit (see methods) which should allow inter-labora-
tory comparison of results, and has been applied in a
number of recent studies of different clinical conditions
either alone [27-31] or together with phenotype studies
[32-35], to demonstrate increased or reduced numbers of
circulating endothelial progenitor cells.
Identification of suitable EPC sources is of the highest
importance as a prerequisite for clinical EPC use, and it
would appear that because of their interrelationship EPC
might be sourced from the HPC sources that have been
employed for autologous haematopoietic reconstitution,
namely bone marrow or PBHPC. Another HPC-rich
source which might be considered as an EPC source is all-
ogeneic umbilical cord blood (CB). However, no clinical
studies of allogeneic EPC graft sources have been reported
to date since they are likely to require continual immuno-
suppression to prevent rejection, and the risk versus ben-
efit of that in likely patient groups has not been assessed.
While poor in HPC, normal peripheral blood mononu-
clear cells may contain other useful stem cells. Different
groups have preferred most of the different autologous
sources or mononuclear cell subpopulations of these as
EPC sources for clinical administration. Such studies have
generally reported clinical benefit but have not demon-
strate any obvious relative advantage or disadvantage of
any source over another in clinical vasculogenesis in myo-
cardial or severe limb ischaemia [36-43], including HPC-
poor normal peripheral blood mononuclear cells follow-
ing ex vivo conditioning [37].
Since therapeutic EPC would be better sourced from
patients themselves, there is concern that some patients
requiring vascular regeneration may have numerically or
functionally compromised EPC which contributes to theirJournal of Translational Medicine 2007, 5:37 http://www.translational-medicine.com/content/5/1/37
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clinical condition, and that they should be assessed for
this. It may be that alternate autologous sources or ex vivo
expansion or maturation might enhance the EPC poten-
tial of grafts in such cases. It is also probable that any clin-
ical effect will be dependent on the dose and activity of the
effector cells. While clinical vasculogenesis does not yet
appear to have an equivalent determinant to CD34 phe-
notype as used for clinical HPC graft assessment of
potency for haematopoietic reconstitution[7], the most
prevalent  in vitro assays to determine EPC number or
potency which are emerging in practise are the immu-
nophenotype assay based on combinations of expression
of VEGFR2 and CD34 and/or CD133, and the CFU-EPC
assay described by Hill et al[27]. We have therefore used
these assays to compare putative EPC numbers in poten-
tial clinical sources of EPC, namely the HPC-rich autolo-
gous sources bone marrow and G-CSF-mobilised
peripheral blood, HPC-rich allogeneic umbilical cord
blood, and HPC-poor autologous normal peripheral
blood.
Methods
Collection of samples
Venous blood samples (10 ml) were collected in heparin
from healthy blood donors (normal peripheral blood,
nPB) and immediately following cell-separator leuka-
pheresis collection of G-CSF mobilised peripheral blood
(mPB) from patients for autologous transplant (mPBp)
and from healthy donors for allogeneic transplant
(mPBd). Cord blood (CB) products (20–50 ml) were
aspirated from the umbilical placental veins from normal
caesarean deliveries. Bone marrow (BM) samples (3 ml)
were obtained by aspiration from the posterior iliac crest
of haematologically normal donors. Appropriate ethics
committee approval was obtained and written informed
consent from each patient.
Flow cytometry analysis
Cells were phenotyped in the whole blood samples by
flow cytometry. Cells were directly stained and analysed
for phenotypic expression of surface markers using anti-
human monoclonal antibodies (MAbs) conjugated to
phycoerythrin (PE), fluorescein isothiocynate (FITC),
Peridin Chlorophylla protein (PerCP) or Allophycocy-
anin (APC). The MAbs used included anti-CD45-PerCP,
anti-CD34-FITC, (Becton Dickinson, Oxford, UK), anti-
VEGFR2-PE (R&D systems, UK), and anti-CD133-APC
(Myltenyi Biotec, UK). Negative controls without anti-
body were used to establish positive stain boundaries,
having first confirmed that tests without antibody did not
differ from tests with appropriate isotype non-specific
antibody controls in samples stained in whole blood in
preliminary experimentation. Samples were stained with
none, single, double, triple and quadruple antibodies
over the sequence none, CD45, CD34, CD133 and
VEGFR2, in a five tube panel. 100 ul of undiluted blood
sample was stained with appropriate amounts of antibod-
ies for 30 minutes in the dark; erythrocytes were lysed
using lysing solution (Becton Dickinson, UK) for 20 min-
utes in the dark. Samples were then centrifuged at 200 g
for 10 minutes and washed twice with phosphate buffered
saline (PBS). The cell pellets were resuspended in Cell Fix
solution (Becton Dickinson, UK). For each sample
50,000–100,000 events (of viable cells only), were
acquired using a FACSCalibur flow cytometer and Cel-
lQuest software (Becton Dickinson, UK). The viable leu-
cocytes were defined by forward versus side-scatter
distribution and CD45 expression, which was related to
total white count to determine absolute numbers. Other
cells were determined as a proportion of total leucocytes
from which their absolute numbers could be calculated.
CD34, CD133 and VEGFR2 staining was checked with
and without CD45 gating to ensure no rare CD45-nega-
tive cells expressing these markers were present.
Colony Forming Units-Endothelial Progenitor Cells (CFU-
EPC)
This assay is based on that described by Hill et al[27] but
is carried out using commercial kit reagents according to
the manufacturers recommendations (CFU-Hill, StemCell
Technologies, UK). Mononuclear cells were isolated by
buoyant-density centrifugation and resuspended at 2.5 ×
106 cells/ml in Complete Endothelial Culture Medium
(CECM) comprising Endocult Basal Medium (StemCell
Technologies, UK) supplemented with 1/5 dilution of
Endocult supplements (StemCell Technologies, UK) and
plated at 2 ml/well in fibronectin-coated 6-well plates
(Becton Dickinson, UK) and incubated for two days at 37
C, 5% CO2 with 95% humidity. After two days, when
mature endothelial cells and monocytes had adhered[27],
the non-adherent cells containing EPC were removed,
counted and resuspended at 0.5 to 1 × 106 cells/ml in fresh
CECM in fibronectin-coated 24-well plate at 1 ml/well
(Becton Dickinson, UK) for a further three days at 37 C,
5% CO2 with 95% humidity. The colonies per well were
then identified and counted, and the results were
expressed as colonies per million non-adherent cells
plated. The typical colonies were defined following the
published method[27] and StemCell Technologies' tech-
nical manual as a central core of "round" cells surrounded
by elongated "sprouting" cells at the periphery and are
classified as colony forming unit endothelial progenitor
cell (CFU-EPC).
Statistical analysis
The different sets of results were compared using non-par-
ametric tests (Wilcoxon matched pairs test or Mann-Whit-
ney test, depending on whether pairing was possible).
GraphPad or NCSS statistical software packages were
used.Journal of Translational Medicine 2007, 5:37 http://www.translational-medicine.com/content/5/1/37
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Results
Assessment of CD34+ cells
The expression of CD34 on leukocytes was analysed in 10
bone marrow (BM); 21 cord blood (CB); and 27 mobi-
lised peripheral blood samples from patients for autolo-
gous transplant (mPBp). The results showed that mPBp
had significantly higher numbers of CD34+ than BM and
CB (Figure 1a). Normal peripheral blood (not mobilised)
(nPB) (n = 16) contained a very low number of CD34+
cells compared to the other sources (Figure 1a). Studies
were also conducted on mobilised peripheral blood of
healthy allogeneic HPC donors (mPBd), but these present
at a much lower frequency than patients for autograft. In
all cases throughout this study mPBd showed similar
results to mPBp, but results are generally not presented
here because numbers were too low for meaningful statis-
tical analysis. mPBd results from a larger series will be pre-
sented in a subsequent paper which focuses on the effect
of G-CSF administration on circulating EPC (manuscript
in preparation).
Assessment of CD133+ cells
The expression of CD133 on leukocytes was analysed in 8
bone marrow (BM), 7 cord blood (CB), and 7 mobilised
peripheral blood samples from patients for autologous
transplant (mPBp). The distribution of CD133+  cells
between sample groups was similar to that of CD34+ cells
in that again the highest number of CD133+ cells was seen
in mPBp samples (Figure 1b), suggesting that G-CSF
administration mobilises CD34+ and CD133+ cells in sim-
ilar ways. Similarly to CD34+  cells, the numbers of
CD133+ cells in normal peripheral blood (nPB: n = 16)
were very low compared to the other sources tested (Fig-
ure 1b).
Assessment of CD133 and CD34 co-expression
Analysis of CD133 expression by CD34+ cells in each sam-
ple group showed that mobilised blood samples (mPB)
(79.8%) had markedly higher co-expression of CD133 by
CD34+ cells as compared to CB (53%), BM (13%) or nPB
(11%) (Table 1). The relative proportions of the
Table 1: Percentage of cells expressing CD34 and/or CD133 in haematopoietic stem cell clinical transplant sources and normal blood.
Sources BM CB mPBP nPB
total leucocytes/ml (106) 1.63 (0.3)
n = 10
1.54 (0.4)
n = 21
1.41 (0.26)
n = 27
1.17 (0.41)
n = 16
CD34+ (% of wbc) 0.71 (0.1)
n = 10
0.42 (0.04)
n = 21
1.46 (0.36)
n = 27
0.09 (0.02)
n = 16
CD133+ (% of wbc) 0.46 (0.07)
n = 8
0.4 (0.05)
n = 7
1.04 (0.2)
n = 7
0.07 (0.01)
n = 16
CD133+ (% of CD34+) 13 (5.65)
n = 8
53 (6.14)
n = 7
79.76 (5.5)
n = 7
11 (3.96)
n = 16
Percentages of cells expressing CD34 and/or CD133 alone or together were compared between the various sources tested. Normal (non-
mobilised) peripheral blood (nPB), bone marrow (BM), umbilical cord blood (CB) and G-CSF-mobilised peripheral blood samples (mPBP). Results 
are expressed as the mean (standard error); n = number of samples tested. White blood cells (wbc) are all leucocytes in the samples analysed, 
including mononuclear and granulocytic populations.
Expression of CD34 or CD133 markers in haematopoietic  stem cell clinical transplant sources and normal blood Figure 1
Expression of CD34 or CD133 markers in haemat-
opoietic stem cell clinical transplant sources and nor-
mal blood. Total numbers of cells expressing CD34 (a) or 
CD133 (b) in the different sources tested. Sources were nor-
mal (non-mobilised) peripheral blood (nPB), bone marrow 
(BM), umbilical cord blood (CB) and G-CSF-mobilised 
peripheral blood samples (mPBP) from patients for autolo-
gous grafts.
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CD34+CD133-  CD34+CD133+  and CD34-CD133+  sub-
populations of cells for each group are shown in Figure 2.
In mobilised peripheral blood the jointly-expressing
CD34+CD133+ cells are the major subpopulation, true for
both patients and healthy adult PBHPC donors, whereas
in bone marrow and in normal peripheral blood the
jointly-expressing cells are a minor subpopulation, out-
numbered by both singly-expressing CD133+(CD34-) and
CD34+(CD133-) populations of which the
CD34+(CD133-) is the major subpopulation. Cord blood
shows an intermediate pattern of subpopulation repre-
sentation.
Assessment of the total numbers of CD34+ and/or CD133+ 
cells co-expressing VEGFR2 in the different sources
Mobilised peripheral blood (mPB) was the source with
the highest number of CD34+ and/or CD133+ cells co-
expressing VEGFR2 compared to the other sources tested
(Figure 3a, b, c). The total number of CD34+ and/or
CD133+ cells co-expressing VEGFR2 in normal peripheral
blood was in all cases significantly lower than mobilised
peripheral blood.
Proportions of CD34+ and/or CD133+ cells co-expressing 
VEGFR2 in the different sources
Proportions of CD34+ and/or CD133+ cells which co-
express VEGFR2 varied between sources. In CD34+-rich
sources (i.e. excluding nPB), CB (8.93%) was the source
with the highest percentage of CD34+ cells expressing
VEGFR2, compared to BM (5.43%), mPBp (3.92%) (Fig-
ure 3d). Although CB had the highest percentage of
CD34+VEGFR2+ cells, it was the HPC source with the low-
est absolute number of CD34+ cells and therefore showed
no significant difference from BM and mPB samples in
terms of numbers of CD34+VEGFR2+ cells (Figure 3a).
The percentage of CD34+ or CD133+ cells co-expressing
VEGFR2 was significantly higher in normal peripheral
blood than in any other source tested (Figure 3d, e). How-
ever, due to the very low number of CD34+ or CD133+
cells in nPB, the total number of CD34+ or CD133+ cells
co-expressing VEGFR2 was significantly lower than in CB,
mPB or BM (Figure 3a, b).
Quantification of CD34+VEGFR2+ cells as a proportion of
the CD133+ cells (CD34+VEGFR2+CD133+) was almost
below limits of detection by flow cytometry when acqui-
sition of a minimum of 50,000–100,000 leukocyte events
was used. Apparently similar proportions of
CD34+VEGFR2+CD133+ cells were found between the dif-
ferent sources tested, with BM being the source with the
lowest proportion compared to the other sources tested
(Figure 3f).
Frequencies of CFU-EPC in sources of HPC and in normal 
peripheral blood
Normal peripheral blood, where the total numbers of
CD34+ and CD133+ cells alone or co-expressing VEGFR2
are very low, gave the highest frequency of CFU-EPC
Number and percentage of putative EPC characterised by dif- ferent phenotypic definitions in haematopoietic stem cell  clinical transplant sources and normal blood Figure 3
Number and percentage of putative EPC character-
ised by different phenotypic definitions in haemat-
opoietic stem cell clinical transplant sources and 
normal blood. Number 3a) and percentage 3d) of CD34+ 
cells co-expressing VEGFR2 in the different sources tested.; 
Number 3b) and percentage 3e) of CD133+ cells co-
expressing VEGFR2 in the different sources tested and 
Number 3c) and percentage 3f) of CD34+CD133+ cells co-
expressing VEGFR2 in the different sources tested. Note dif-
ferent Y axis scales between figures.
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Relative proportions of CD34+ and/or 133+ cells in different  sources Figure 2
Relative proportions of CD34+ and/or 133+ cells in 
different sources. Percentages (of their summed popula-
tions) of CD34+ cells negative for CD133 expression (blue), 
CD133+ cells negative for CD34 expression (yellow) and 
cells co-expressing CD133 and CD34 markers (green) were 
compared between various haematopoietic stem cell clinical 
transplant sources and normal blood. Normal (non-mobi-
lised) peripheral blood (nPB), bone marrow (BM), umbilical 
cord blood (CB) and G-CSF-mobilised peripheral blood sam-
ples (mPBp, autologous patients; or mPBd, allogeneic 
donors).
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(39.37 CFU-EPC/106  cells plated), (Figure 4). Thus,
approximately 1 in 25,000 mononuclear cells (0.004%)
in normal peripheral blood had the potential to prolifer-
ate and generate endothelial colonies, which is of the
order of magnitude of HPC subpopulations found in nor-
mal peripheral blood. By contrast, the sources known to
be rich in CD34+ and/or CD133+ (i.e. mPB, BM and CB)
had much lower numbers of CFU-EPC. Of these sources,
bone marrow gave the highest frequency of CFU-EPC,
cord blood was lower, and G-CSF mobilised peripheral
blood, the source with the highest number of cells
expressing CD34 and/or CD133 jointly expressing
VEGFR2, was virtually incapable of forming colonies. This
was similar for both (autologous) patient (mPBp) or (all-
ogeneic) healthy PBHPC donors (mPBd) (BM:15.7 CFU-
EPC/106 cells plated; CB:6.4 CFU-EPC/106 cells plated;
mPBp: 0.9 CFU-EPC/106 cells plated; mPBd: 0.6 CFU-
EPC/106 cells plated) (Figure 3). Where CFU-EPC from
bone marrow, cord blood or mobilised peripheral blood
sources were seen they were morphologically different
and much smaller than those generated from peripheral
blood mononuclear cells. Individual cord blood cells also
acquired spindle-shaped morphology under colony assay
culture conditions while most of those from G-CSF mobi-
lised samples remained rounded.
Lack of correlation between any of the published 
immunophenotypic definitions of EPC progenitors and 
their ability to generate CFU-EPC
As well as the obvious contrast between the different
sources in their content of putative EPC defined by CFU-
EPC or defined by immunophenotypic assays, neither the
proportions nor the absolute total numbers of subpopu-
lations expressing CD34 or CD133 or VEGFR2 singly or in
any joint combination showed any significant correlation
with the number of endothelial progenitor cell colonies
generated within or across any of the sources studied. The
only trend that was found was between falling mean CFU-
EPC numbers and falling mean CD14+ cell proportions
(of mononuclear cells) across normal peripheral blood,
bone marrow and cord blood, respectively. This excluded
G-CSF-mobilised peripheral blood whose mean CD14+
cell proportions were similar to normal peripheral blood,
but whose mean CFU-EPC numbers were least of all the
groups. Neither mean nor individual values for CFU-EPC
and CD14+ proportions reached significance, but CD14
evaluation was introduced late in the study and only 5
individuals were evaluated in each category.
Discussion
We have investigated the presence of currently proposed
EPC phenotypes in the most common and practicable
available sources of these cells for clinical use. All sources
except normal peripheral blood (nPB) had high numbers
of CD34+ and CD133+ cells which are generally regarded
as correlates of haematopoietic progenitor cells (HPC),
with mobilised peripheral blood (mPB) the source that
had significantly higher total numbers of CD34+  and
CD133+ by comparison to the other sources. mPB had 10
times more CD34+ and CD133+ cells/ml (205.8 and 146.6
× 103 cells/ml respectively) than normal peripheral blood.
We found that the PBHPC were predominantly CD34+
cells which co-expressed CD133, whereas these were in a
minority in HPC in bone marrow or normal peripheral
blood where singly expressing CD34+ or CD133+ were in
the majority. These results agree very closely with that of
De Wynter et al[44] who showed that 75% of CD34+ from
post-G-CSF apheresis samples were CD133+ compared
with 50% in CB and 35% in BM: normal peripheral blood
was not studied. Results from mobilised peripheral blood
samples for both patients donating PBHPC for autografts
and healthy allogeneic PBHPC donors are similar, and
indicates that these findings are not a reflection of under-
lying differences arising from any preceding therapy for
patients' leukaemias. These phenomena relating to
changes in HPC and EPC following G-CSF administration
have been more extensively characterised by us (manu-
script in preparation), and their underlying processes are
under investigation.
Endothelial progenitor cell colony assay (CFU-EPC) in hae- matopoietic stem cell clinical transplant sources and normal  blood Figure 4
Endothelial progenitor cell colony assay (CFU-EPC) 
in haematopoietic stem cell clinical transplant 
sources and normal blood. Endothelial progenitor cell 
colonies (CFU-EPC) per 106 cells plated in the different 
sources tested. Normal peripheral blood (nPB)(n = 15), bone 
marrow (BM)(n = 7), cord blood (CB)(n = 11) and G-CSF-
mobilised peripheral blood samples (mPBP, patient (n = 11); 
or mPBD, donor (n = 5)). (*** p < 0.001, Mann-Whitney 
test).
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It is currently believed that endothelial progenitor cells
(EPC) are a subpopulation of CD34+ and/or CD133+
which express the more specific endothelial marker
VEGFR2. In our study mobilised peripheral blood was the
source found to have the highest number of CD34+ and/
or CD133+ cells alone or in combination with VEGFR2
expression whereas normal peripheral blood was found to
have the lowest numbers, mainly due to the low HPC
numbers in normal peripheral blood. When proportions
are considered, normal peripheral blood has the highest
proportions of CD34+ cells or CD133+ cells which jointly
express VEGFR2. However these overlap very little into
cells expressing all three markers.
Since it has also been widely reported that EPC can be
measured by an EPC colony assay (CFU-EPC)
[29,30,32,33,35,45-49], this was also evaluated, to deter-
mine whether a phenotype-based or colony-based assay
might be best for adoption by us for routine measurement
of EPC in different clinical samples. Measurement of CFU-
EPC can identify very low frequencies of such cells since
individual colonies are obvious, and may provide a sensi-
tive indicator of the capacity of mononuclear cells to pro-
duce endothelial cells. This assay has been used in a
number of studies to measure CFU-EPC in different clini-
cal situations and in healthy individuals for comparison
since it was first described by Hill et al[27]. These studies
measure CFU-EPC in normal peripheral blood as some
means of assessing vasculogenic potency, and reduced
numbers have been found in clinical conditions associ-
ated with ischaemic disease [27,50-54].
Since EPC have been associated with HPC, which are low
in normal peripheral blood having less than one tenth of
the numbers of CD34+ and/or CD133+ cells compared
with the other sources, it was surprising to find that nor-
mal peripheral blood mononuclear cells was the source
with the highest number of CFU-EPC. Of the HPC-rich
sources, bone marrow was identified as the best source of
CFU-EPC as compared to both cord blood and mobilised
peripheral blood from both patients and allogeneic
healthy donors, but never as high as normal peripheral
blood. We have not found a correlation between numbers
of CFU-EPC and the number of cells expressing CD34 and
CD133 either alone or in combination, or in combination
with expression of VEGFR2.
The contrast between normal peripheral blood having the
greatest number of CFU-EPC and very few HPC, while
mobilised PBHPC contain the most HPC but are virtually
devoid of CFU-EPC, is striking. This would seem to indi-
cate that CFU-EPC and EPC defined by immunopheno-
type are not the same subpopulations of mononuclear
leukocytes in peripheral blood. Similar results were
obtained by George et al[55], who suggest that while phe-
notype may provide numerical data, the CFU-EPC assay
may provide some functional measure of their ability to
proliferate. Others suggest that CFU-EPC are derived from
CD14+ monocyte-like cells [56-58], and while their con-
tribution to vasculogenesis (and the relevance of the CFU-
EPC assay) is disputed[59], it appears that there is a con-
tribution to vasculogenesis by some CD14+ cells[58,60-
63]. This could explain why HPC-poor normal peripheral
blood mononuclear cells can be as effective as bone mar-
row or enriched PBHPC in eliciting vasculogenesis in clin-
ical or laboratory model ischaemia [37,64-66]: however,
these appear to require ex vivo maturation or expansion to
be effective. Our findings that the numbers of CFU-EPC in
normal peripheral blood, bone marrow and cord blood
reflect the proportions of CD14+ cells in these mononu-
clear leukocyte sources may support this, but the fall that
we find in peripheral blood CFU-EPC following adminis-
tration of G-CSF appears to put PBHPC into a different
category, perhaps reflecting the different CD34+/CD133+
expression, and this is under further investigation by us.
Even within immunophenotypically defined subpopula-
tions it is evident that the different sources differ in char-
acter, especially in whether CD34 and CD133 are
expressed uniquely or jointly. If only one or other of these
is assessed for co-expression of VEGFR2, it may be that for
mobilised PBHPC that may encompass most VEGFR2-
expressing HPC, whereas for normal peripheral blood or
bone marrow a significant population of VEGFR2-
expressing HPC would go undetected. The situation for
cord blood appears to be intermediate. Most studies indi-
cate that CD34+/CD133+/VEGFR2+ cells can differentiate
in vitro into cells expressing mature endothelial markers
and that in general CD133 expression is lost during this
process [67-70]. However, there are some studies which
suggest that many HPC are plastic and that such markers
can be up-regulated or down-regulated [10,16,18].
A number of recent clinical studies have employed autol-
ogous sources of haematopoietic stem cells to elicit appar-
ent revascularisation of ischaemic tissues. However, there
is no consistent definition of which cells are active in this
revascularisation. If CFU-EPC reflects clinically relevant
circulating EPCs it could be that peripheral blood mono-
nuclear cells would be a better source of EPC for vascular
repair/regeneration in a clinical setting and that G-CSF
mobilised HPC might be the worst source of EPC. How-
ever laboratory models and clinical studies indicate that
bone marrow or peripheral blood HPC selected by either
CD34 or CD133 phenotype, or normal peripheral blood
mononuclear cells matured ex vivo on fibronectin in
"endothelial" cultures, are all effective in vasculogenesis.
These EPC definitions need further clarification. We have
undertaken overlapping complementary studies employ-
ing different cell subset enrichment and depletion whichJournal of Translational Medicine 2007, 5:37 http://www.translational-medicine.com/content/5/1/37
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will expand on this (manuscript in preparation), and we
continue to develop these in different models of vasculo-
genesis which may more directly reflect mature endothe-
lial cell function.
Conclusion
It has been proposed that EPC can be defined as cells
expressing VEGFR2 (KDR) and one or both of the HPC
markers CD34 and CD133. Cells expressing all three
markers are very rare in any of the cell sources studied, but
cells expressing VEGFR2 and either CD34 or CD133 are
found and are most frequent in mobilised peripheral
blood, following administration of G-CSF. That mobi-
lised peripheral blood is the cell source with the lowest
frequency of EPC as defined by CFU-EPC, while normal
blood has the highest frequency of CFU-EPC yet by far the
lowest frequency of any cells expressing HPC markers
(CD34 or CD133), suggests that the phenotypically
defined cells are distinct from the functionally defined
CFU-EPC. Other relevant phenotypically defined charac-
teristics, such as the degree of overlap of CD34 and
CD133 expressing cells (joint expression of these HPC
markers), differ in the different cell sources. There is no
implication from the published clinical studies that any of
these definitions of EPC reflects the actual vasculogenic
capacity of a cell source, and the clinical evidence suggests
that EPC are ubiquitous in peripheral blood and bone
marrow and heterogeneous in character. Further studies
are required to establish laboratory assays for EPC for
measuring vasculogenic potency of clinical autograft cells
that will be the equivalent of measuring CD34-expressing
cells to assess haematopoietic potential. The relevance of
the CFU-EPC assay is not established and requires defini-
tion of the cells which initiate EPC colony formation. The
proposed phenotype assays are neither explicit nor com-
prehensive, and probably require more complex pheno-
type analysis or the identification of some exclusive
marker which is a correlate of some directly measured
aspect of vasculogenesis.
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